Abstract
AbstractThe purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA.
Funder
Cancerfonden
Fru Berta Kamprads Stiftelse
Lund University
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Reference206 articles.
1. Kondev FG. Nuclear Data Sheets for A=177. Nuclear data sheets. 2019;159: 147–9. https://doi.org/10.1016/j.nds.2019.100514
2. Berger MJH, J.H. Seltzer, S.M. Chang, J. Coursey, J.S. Sukumar, R. Zucker, D.S. Olsen, K. XCOM: Photon cross section database (version 1.5). http://physics.nist.gov/xcom National Institute of Standards and Technology, Gaithersburg, MD; 2010.
3. Kondev FG, Ahmad I, Carpenter MP, Greene JP, Janssens RV, Lauritsen T, et al. Gamma-ray emission probabilities in the decay of (177m)Lu. Appl Radiat Isot. 2012;70(9):1867–70.
4. Gleisner KS, Brolin G, Sundlov A, Mjekiqi E, Ostlund K, Tennvall J, et al. Long-term retention of 177Lu/177mLu-DOTATATE in patients investigated by gamma-spectrometry and gamma-camera imaging. J Nucl Med. 2015;56(7):976–84.
5. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24(4):368–71.
Cited by
65 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献